SMT201800036T1 - Combinazioni di agonisti di recettore 5-ht4 e inibitori di acetilcolinesterasi per il trattamento di disturbi cognitivi - Google Patents
Combinazioni di agonisti di recettore 5-ht4 e inibitori di acetilcolinesterasi per il trattamento di disturbi cognitiviInfo
- Publication number
- SMT201800036T1 SMT201800036T1 SM20180036T SMT201800036T SMT201800036T1 SM T201800036 T1 SMT201800036 T1 SM T201800036T1 SM 20180036 T SM20180036 T SM 20180036T SM T201800036 T SMT201800036 T SM T201800036T SM T201800036 T1 SMT201800036 T1 SM T201800036T1
- Authority
- SM
- San Marino
- Prior art keywords
- combinations
- treatment
- receptor agonists
- cognitive disorders
- acetylcholinesterase inhibitors
- Prior art date
Links
- 108091005482 5-HT4 receptors Proteins 0.000 title 1
- 239000000544 cholinesterase inhibitor Substances 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16874109P | 2009-04-13 | 2009-04-13 | |
| US29255910P | 2010-01-06 | 2010-01-06 | |
| PCT/US2010/030760 WO2010120695A2 (en) | 2009-04-13 | 2010-04-12 | 5-ht4 receptor agonist compounds for treatment of cognitive disorders |
| EP10713790.3A EP2419104B1 (en) | 2009-04-13 | 2010-04-12 | Combinations of 5-ht4 receptor agonists and acetylcholinesterase inhibitors for treatment of cognitive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201800036T1 true SMT201800036T1 (it) | 2018-03-08 |
Family
ID=42237213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20180036T SMT201800036T1 (it) | 2009-04-13 | 2010-04-12 | Combinazioni di agonisti di recettore 5-ht4 e inibitori di acetilcolinesterasi per il trattamento di disturbi cognitivi |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8404711B2 (enExample) |
| EP (1) | EP2419104B1 (enExample) |
| JP (1) | JP2012523437A (enExample) |
| KR (1) | KR20120017421A (enExample) |
| CN (2) | CN105832735A (enExample) |
| AU (1) | AU2010236734B2 (enExample) |
| BR (1) | BRPI1013777A8 (enExample) |
| CA (1) | CA2758321A1 (enExample) |
| CY (1) | CY1119800T1 (enExample) |
| DK (1) | DK2419104T3 (enExample) |
| ES (1) | ES2654930T3 (enExample) |
| HR (1) | HRP20180018T1 (enExample) |
| HU (1) | HUE038141T2 (enExample) |
| IL (1) | IL215660A0 (enExample) |
| LT (1) | LT2419104T (enExample) |
| MX (1) | MX2011010782A (enExample) |
| NO (1) | NO2419104T3 (enExample) |
| PL (1) | PL2419104T3 (enExample) |
| PT (1) | PT2419104T (enExample) |
| RU (1) | RU2569056C2 (enExample) |
| SI (1) | SI2419104T1 (enExample) |
| SM (1) | SMT201800036T1 (enExample) |
| WO (1) | WO2010120695A2 (enExample) |
| ZA (1) | ZA201107490B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| CA2744278C (en) | 2008-11-19 | 2015-09-08 | Envivo Pharmaceuticals, Inc. | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| RU2011150248A (ru) * | 2009-05-11 | 2013-06-20 | Энвиво Фармасьютикалз, Инк. | Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы |
| CN103221411B (zh) | 2010-05-17 | 2016-05-11 | 富瑞姆制药公司 | (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型 |
| CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| US10874701B2 (en) | 2012-08-16 | 2020-12-29 | University-Industry Cooperation Group Of Kyung Hee University | Lactic acid bacteria capable of preventing and/or treating senescence and dementia |
| US20150306158A1 (en) | 2012-08-16 | 2015-10-29 | University-Industry Cooperation Group Of Kyung Hee University | Lactic acid bacteria capable of preventing and/or treating senescence and dementia |
| MX385719B (es) | 2017-05-24 | 2025-03-18 | H Lundbeck As | Combinacion de un antagonista del receptor 5-ht6 y un inhibidor de acetilcolinesterasa para su uso en el tratamiento de la enfermedad de alzheimer en una subpoblacion de pacientes portadores de alelos apoe4 |
| SG11201909359YA (en) | 2017-06-01 | 2019-11-28 | Eisai R&D Man Co Ltd | Pharmaceutical composition comprising pde9 inhibitor |
| EP3632431A4 (en) | 2017-06-02 | 2020-06-03 | FUJIFILM Toyama Chemical Co., Ltd. | Agent for preventing or treating brain atrophy |
| SI3661518T1 (sl) * | 2017-07-31 | 2025-01-31 | Alfasigma S.P.A. | Načini zdravljenja simptomov gastropareze z zdravilom velusetrag |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1311272T3 (da) * | 2000-03-03 | 2007-02-26 | Eisai R&D Man Co Ltd | Hidtil ukendte fremgangsmåder hvor der anvendes cholinesteraseinhibitorer |
| TWI351282B (en) * | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| US7598265B2 (en) | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
| TWI377206B (en) * | 2005-04-06 | 2012-11-21 | Theravance Inc | Crystalline form of a quinolinone-carboxamide compound |
| MY147756A (en) * | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
-
2010
- 2010-04-12 HU HUE10713790A patent/HUE038141T2/hu unknown
- 2010-04-12 KR KR1020117026729A patent/KR20120017421A/ko not_active Ceased
- 2010-04-12 JP JP2012504924A patent/JP2012523437A/ja active Pending
- 2010-04-12 RU RU2011146032/15A patent/RU2569056C2/ru not_active IP Right Cessation
- 2010-04-12 PT PT107137903T patent/PT2419104T/pt unknown
- 2010-04-12 CA CA2758321A patent/CA2758321A1/en not_active Abandoned
- 2010-04-12 HR HRP20180018TT patent/HRP20180018T1/hr unknown
- 2010-04-12 LT LTEP10713790.3T patent/LT2419104T/lt unknown
- 2010-04-12 WO PCT/US2010/030760 patent/WO2010120695A2/en not_active Ceased
- 2010-04-12 BR BRPI1013777A patent/BRPI1013777A8/pt not_active IP Right Cessation
- 2010-04-12 MX MX2011010782A patent/MX2011010782A/es active IP Right Grant
- 2010-04-12 AU AU2010236734A patent/AU2010236734B2/en not_active Ceased
- 2010-04-12 SI SI201031632T patent/SI2419104T1/en unknown
- 2010-04-12 CN CN201610257689.5A patent/CN105832735A/zh active Pending
- 2010-04-12 EP EP10713790.3A patent/EP2419104B1/en active Active
- 2010-04-12 SM SM20180036T patent/SMT201800036T1/it unknown
- 2010-04-12 PL PL10713790T patent/PL2419104T3/pl unknown
- 2010-04-12 ES ES10713790.3T patent/ES2654930T3/es active Active
- 2010-04-12 CN CN2010800164976A patent/CN102395371A/zh active Pending
- 2010-04-12 DK DK10713790.3T patent/DK2419104T3/en active
- 2010-04-12 NO NO10713790A patent/NO2419104T3/no unknown
- 2010-04-12 US US12/758,631 patent/US8404711B2/en not_active Expired - Fee Related
-
2011
- 2011-10-10 IL IL215660A patent/IL215660A0/en unknown
- 2011-10-12 ZA ZA2011/07490A patent/ZA201107490B/en unknown
-
2013
- 2013-02-20 US US13/771,685 patent/US20140057939A1/en not_active Abandoned
-
2018
- 2018-01-19 CY CY20181100069T patent/CY1119800T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT2419104T (lt) | 2018-02-12 |
| ES2654930T3 (es) | 2018-02-15 |
| JP2012523437A (ja) | 2012-10-04 |
| NO2419104T3 (enExample) | 2018-04-07 |
| EP2419104B1 (en) | 2017-11-08 |
| RU2011146032A (ru) | 2013-05-20 |
| HUE038141T2 (hu) | 2018-10-29 |
| PL2419104T3 (pl) | 2018-04-30 |
| EP2419104A2 (en) | 2012-02-22 |
| WO2010120695A2 (en) | 2010-10-21 |
| PT2419104T (pt) | 2018-01-31 |
| DK2419104T3 (en) | 2018-02-05 |
| BRPI1013777A2 (pt) | 2016-04-05 |
| CA2758321A1 (en) | 2010-10-21 |
| HRP20180018T1 (hr) | 2018-02-09 |
| IL215660A0 (en) | 2012-01-31 |
| US20100261752A1 (en) | 2010-10-14 |
| CN102395371A (zh) | 2012-03-28 |
| SI2419104T1 (en) | 2018-03-30 |
| MX2011010782A (es) | 2012-01-20 |
| AU2010236734A8 (en) | 2012-02-16 |
| US8404711B2 (en) | 2013-03-26 |
| WO2010120695A3 (en) | 2010-12-02 |
| ZA201107490B (en) | 2012-06-27 |
| AU2010236734A1 (en) | 2011-11-03 |
| CN105832735A (zh) | 2016-08-10 |
| KR20120017421A (ko) | 2012-02-28 |
| US20140057939A1 (en) | 2014-02-27 |
| AU2010236734B2 (en) | 2015-06-11 |
| CY1119800T1 (el) | 2018-06-27 |
| RU2569056C2 (ru) | 2015-11-20 |
| BRPI1013777A8 (pt) | 2017-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE038141T2 (hu) | 5-HT4 receptor agonisták és acetilkolinészteráz inhibitorok kombinációi kognitív rendellenességek kezelésére | |
| PT2467372T (pt) | Tratamento de distúrbios relacionados com bdnf usando laquinimod | |
| EP2293800A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EARLIER DISEASES | |
| IL216140A0 (en) | Egfr inhibitors and methods of treating disorders | |
| ZA201202500B (en) | Use of toll-like receptor and agonist for treating cancer | |
| ZA201001193B (en) | 2-anilinopurin-8-ones as inhibitors of TTK/MPS1 for the treatment of proliferative disorders | |
| EP2456868A4 (en) | METHOD AND COMPOSITIONS FOR TREATING SUFFERING OF SUFFERING THROUGH MUSCARIN RECEPTOR ACTIVATION | |
| IL217777A0 (en) | Methods for treatment of pain | |
| SMT201700451T1 (it) | Antagonisti di wnt e metodi di trattamento | |
| IL216281A0 (en) | Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors | |
| IL214455A0 (en) | Methods and compositions for treatment of neovascularization | |
| ZA201201290B (en) | Methods and compositions for treatment of pulmonary fibrotic disorders | |
| SI2427193T1 (sl) | Uporaba inhibitorjev PDE7 za zdravljenje motenj gibanja | |
| IL214745A0 (en) | Treatment of insulin-resistant disorders | |
| IL219483A0 (en) | Methods and compositions for rapid treatment of otitis externa | |
| EP2475390A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS | |
| IL217297A0 (en) | 5-ht3 receptor modulators, methods of making, and use thereof | |
| ZA201105514B (en) | Use of deferiprone for treatment and prevention of iron-related eye disorders | |
| ZA201202379B (en) | Antagonists of dsgs2 for treatment of cancer | |
| BR112013001939A2 (pt) | tratamento de distúrbios cognitivos com determinados agonistas receptores de ácido alfa-7-nicotínico em combinação com inibidres de acetilcolinesterase | |
| IL209658A0 (en) | Compositions and methods for treatment of ear disorders | |
| HK1167106A (en) | Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors | |
| HK1177888A (en) | 5-ht4 receptor agonists for the treatment of dementia | |
| GB0905954D0 (en) | Treatment of exacerbations of asthma | |
| GB0906222D0 (en) | Methods for screening of therapeutic agents |